• Develop preclinical research plans and manage R&D (See L2B-preclinical services Here) with in depth pharmacological expertise on brain tumors.

• Help you explore Blood Brain Barrier (BBB) opening and crossing options.

• Challenge your plans to increase your technology potential for brain tumors patients.

• Conduct market research: competitive intelligence, product market fit, competitive advantage.

• Reach out for partners among my extended and active network in the field.

• Support medical writing and corporate/charity communication activities.

• Program Expert – clinical stage oncology molecule repositioning on GBM and modification for BBB crossing.

• Project co-lead - efficacy and administration route optimization for a GBM targeting peptide.

• Project lead: complete market study and startup development plan design for a brain cancer diagnostic solution to switch from a technology push to a demand pull with successful VC traction.

• Scientific board member for 2 GBM related project, including the patient association DEDLM.

One of the rare neuro-oncology preclinical PhD with 10+ years hands-on experience having both:

• business mindset: with a master from HEC Paris and multiples experiences as C-level executive in the brain tumor era,

• a patient’s relative experience, bonding with other patients’ families and association to fully understands the clinical practice beyond survival median time.

As a scientist I care about data, embracing complexity.

As a caregiver I integrate subtle emotions, intuition and hope.

As a business woman I’m on a mission to support, accelerate and increase the impact of your solution against brain Cancers by integrating my unique diverse experience.

Life also made me discover the patient's and care taker perspective of brain cancer twice, these life-changing personal experiences opened my expert's view on the disease.  

​

Since then, I've joined several associations and think tanks:
- Patient's association "Des étoiles dans la mer-beat Glioblastoma" 2021-2025: scientific committee, then co-direction of the research committee to establish collaborations between companies and researchers and set up the R&D grants evaluation system 
- Patient's insight group of Paris-Saclay Cancer Campus (PSCC) since 2024: co-redaction of a white paper on best practices in patient and biotech/medtech collaboration ans raising awareness on patient's insight value in drug innovation design.
- fondation "Les enfants de Catherine", investment committee, since 2024
- association Neurovie, 2025: scientific committee and expert patient support 
- company (confidential): patient committee member

​

These activities feed my mission and the relevance of my strategic advises with real life perspective of final users for your therapeutic future product.